Sometimes we don’t share everything we know about a patient with them. We make that decision based on experience and how much data we think a particular patient can understand or use. This is definitely true when we consider using monitoring technology with patients. The use of CGM has definitely …

We recently had a new patient, 75 years of age, who has class I obesity and prediabetes, and has had hypothyroidism for over 25 years. She is very active and has purposely lost weight, about 6 pounds. She told me she has had hair loss over the years and has seen a specialist for this, but lately it's been worse. She takes spironolactone, biotin, and zinc for her hair loss. She wanted to know what she could do about her hair. She is taking 150 mcg levothyroxine and 5 mcg liothyronine.

Richard Bergenstal, MD is an endocrinologist in Minneapolis, Minnesota and is affiliated with Park Nicollet Methodist Hospital. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice for more than 20 years. Dr. Bergenstal accepts several types of health insurance, listed below. He is one of 5 doctors at Park Nicollet Methodist Hospital who specialize in Endocrinology, Diabetes & Metabolism.

In this week's Homerun Slides,  we conclude this series with blinded versus unblinded CGM and CGM utilization.

Several studies, culminating in the large and definitive Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study have established that hyperglycemia is the major risk factor for microvascular diabetic complications. Chronic hyperglycemia also seems to be a significant and independent, albeit weaker risk factor for macrovascular disease. Other adverse consequences of hyperglycemia include an increased susceptibility to infections.

In this Exclusive Interview transcript, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about emerging automated insulin delivery devices and a dual pathway approach for CGMS and medications.

In this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about emerging automated insulin delivery devices.

In part 1 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about emerging automated insulin delivery devices and the impact of CGM use on blood sugar management.

In part 2 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the educational benefit from using CGM for type 2 diabetes.

In part 3 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the promising innovations and studies being shared with diabetes professionals.